Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/19/2008

SEATTLE, June 19 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2009. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.2 million in exchange for committed research services through Dec. 22, 2009.

"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."

In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such prod
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
3. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
4. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
5. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
6. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
7. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today ... Heaton to the Board of Directors. QMC also announced formation ... , QMC Chief Science Officer and Board of Directors Member, along ... Rice University and Mr. Tomio Gotoh , a pioneer of ... " Quantum Materials welcomes two new outside Board members, ...
(Date:7/22/2014)... , July 22, 2014 ... and device company focused on solid dose formulations ... novel solid formulation of octreotide acetate achieved successful ... with the currently marketed liquid product (Sandostatin®).  Based ... the formulation production process to a contract manufacturing ...
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a ... supplements , will celebrate its first anniversary in August. ... is designed to enhance the body,s ability to produce ... that is made up of a variety of phytonutrients ... have been found to increase nitric oxide ...
Breaking Medicine Technology:Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2
(Date:7/22/2014)... American Society of Hematology (ASH) will present the Society,s ... Lifetime Achievement in Hematology, to Kanti R. Rai, MD, ... of Medicine for his 50-year career combining landmark clinical ... exceptional patient care. , The Wallace H. Coulter ... an individual who has been a vital contributor to ...
(Date:7/22/2014)... 22, 2014 SIMpalm, a ... payment app for Forte Payment System. Forte Mobile Payment ... payments on iPhone, iPod and iPad. The app ... recently updated by SIMpalm. This update was for iOS ... supported on iOS 4.3 and is available to download ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... 27 Ten Big Brothers Big Sisters agencies will receive ... "engaging parents as partners" to help children improve their odds ... Sisters is the nation,s largest donor-supported volunteer mentoring network with ... incarcerated parents, with a focus on breaking negative cycles. ...
... , , ISELIN, N.J., Aug. 27 ... for PharmSep: LCGC,s Symposium for Separation Scientists in Pharmaceuticals. The ... DeLand, Pharmaceutical Market Development Manager, Dionex Corporation , and ... will take place in Philadelphia, PA, on September 21-22, 2009. ...
... , , , ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic ... organization has signed a Master Services Agreement (MSA) to use ... Thorough QT (TQT) and Phase 1 studies delivered by its ...
... Dr. ... win the battle against the epidemic of untreated sleep apnea by offering special incentives to ... ... Southern California sleep apnea expert, has found a way to help patients win the battle ...
... ... Announcing an exciting innovation in antimicrobial coatings: OxiTitan VLR. The ... power of light. Durable and easily applied to existing interior surfaces ... utilizing normal incandescent or flourescent lighting. The continuously active photocatalyst traps ...
... ... reduce operating costs and improve efficiencies for homecare providers. , ... (Vocus) August 27, ... improve productivity for homecare providers., , , , ,According to Spencer Kay, President ...
Cached Medicine News:Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 2Health News:10 Big Brothers Big Sisters Agencies to Receive 2009 Annie E. Casey Family Strengthening Award 3Health News:LCGC Announces the Agenda for Their Upcoming PharmSep Conference 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 2Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 3Health News:NewCardio Announces Master Services Agreement With Top-Three Contract Research Organization 4Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 2Health News:Sleep Apnea Expert Offers Incentives That Could Save Lives 3Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 2Health News:EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 3Health News:New Fastrack Technology Improves Productivity 2Health News:New Fastrack Technology Improves Productivity 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: